These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege. Chen PW; Uno T; Ksander BR Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898 [TBL] [Abstract][Full Text] [Related]
7. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. Repp AC; Mayhew ES; Apte S; Niederkorn JY J Immunol; 2000 Jul; 165(2):710-5. PubMed ID: 10878343 [TBL] [Abstract][Full Text] [Related]
8. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366 [TBL] [Abstract][Full Text] [Related]
9. [Immunological studies in intraocular tumors]. Kotelianskiĭ EO Oftalmol Zh; 1982; 37(1):54-8. PubMed ID: 7043350 [No Abstract] [Full Text] [Related]
16. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866 [TBL] [Abstract][Full Text] [Related]
17. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Chen PW; Ksander BR Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019 [TBL] [Abstract][Full Text] [Related]
18. Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages. Miller MR; Mandell JB; Beatty KM; Harvey SA; Rizzo MJ; Previte DM; Thorne SH; McKenna KC Cancer Immunol Res; 2014 Dec; 2(12):1175-85. PubMed ID: 25248763 [TBL] [Abstract][Full Text] [Related]
19. Characterisation of ocular melanoma with cutaneous melanoma antibodies. Bomanji J; Garner A; Prasad J; Albert DM; Hungerford JL; Granowska M; Britton KE Br J Ophthalmol; 1987 Sep; 71(9):647-50. PubMed ID: 3311140 [TBL] [Abstract][Full Text] [Related]
20. Immune privilege to MHC-disparate tumor grafts in the anterior chamber of the eye. I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response. Ksander BR; Streilein JW Transplantation; 1989 Apr; 47(4):661-7. PubMed ID: 2523103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]